title: Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer.
authors.affiliation: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230-1439, USA.
authors.forename: Alberto
authors.initials: A
authors.lastname: Montero
authors.forename: Daniel
authors.initials: D
authors.lastname: Booser
authors.forename: Laura
authors.initials: L
authors.lastname: Esparza-Guerra
authors.forename: James
authors.initials: J
authors.lastname: Murray
authors.forename: Marguerite
authors.initials: M
authors.lastname: Rosales
authors.forename: Gabriel
authors.initials: G
authors.lastname: Hortobagyi
authors.forename: Vicente
authors.initials: V
authors.lastname: Valero
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D043823:Taxoids; D000077143:Docetaxel; C081222:sargramostim; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor